Overview

  • Product name
    Anti-Tau (phospho S356) antibody
    See all Tau primary antibodies
  • Description
    Rabbit polyclonal to Tau (phospho S356)
  • Host species
    Rabbit
  • Specificity
    ab75603 detects endogenous levels of Tau only when phosphorylated at serine 356.
  • Tested applications
    Suitable for: ICC/IF, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic phosphopeptide derived from human Tau around the phosphorylation site of serine 356 (I-G-SP-L-D).

  • Positive control
    • Extracts from rat brain tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab75603 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/100 - 1/200.
WB 1/500 - 1/1000. Predicted molecular weight: 79 kDa.

Target

  • Function
    Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
  • Tissue specificity
    Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
  • Involvement in disease
    Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
    Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
    Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
    Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
    Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
  • Sequence similarities
    Contains 4 Tau/MAP repeats.
  • Developmental stage
    Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
  • Domain
    The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
  • Post-translational
    modifications
    Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
    Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
    Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
  • Cellular localization
    Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
  • Information by UniProt
  • Database links
  • Form
    There are 9 isoforms produced by alternative splicing.
  • Alternative names
    • AI413597 antibody
    • AW045860 antibody
    • DDPAC antibody
    • FLJ31424 antibody
    • FTDP 17 antibody
    • G protein beta1/gamma2 subunit interacting factor 1 antibody
    • MAPT antibody
    • MAPTL antibody
    • MGC134287 antibody
    • MGC138549 antibody
    • MGC156663 antibody
    • Microtubule associated protein tau antibody
    • Microtubule associated protein tau isoform 4 antibody
    • Microtubule-associated protein tau antibody
    • MSTD antibody
    • Mtapt antibody
    • MTBT1 antibody
    • MTBT2 antibody
    • Neurofibrillary tangle protein antibody
    • Paired helical filament tau antibody
    • Paired helical filament-tau antibody
    • PHF tau antibody
    • PHF-tau antibody
    • PPND antibody
    • PPP1R103 antibody
    • Protein phosphatase 1, regulatory subunit 103 antibody
    • pTau antibody
    • RNPTAU antibody
    • TAU antibody
    • TAU_HUMAN antibody
    • Tauopathy and respiratory failure, included antibody
    see all

Images

  • All lanes : Anti-Tau (phospho S356) antibody (ab75603) at 1/500 dilution

    Lane 1 : Mouse brain tissue with Blocking peptide
    Lane 2 : Mouse brain tissue

    Predicted band size: 79 kDa

  • ab75603 at 1/100 dilution staining Tau (phospho S356) in human Hela cells by ICC/IF.

References

This product has been referenced in:
  • Cao L  et al. Pseudo-phosphorylation at AT8 epitopes regulates the tau truncation at aspartate 421. Exp Cell Res 370:103-115 (2018). Read more (PubMed: 29908160) »
  • Wei Y  et al. Oxidation of KCNB1 channels in the human brain and in mouse model of Alzheimer's disease. Cell Death Dis 9:820 (2018). Read more (PubMed: 30050035) »
See all 4 Publications for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A

Question
Answer



Voici la liste des 4 anticorps de lapin anti-Tau testés et garantis en ICC/IF et chez la souris que nous avons dans notre catalogue :

ab30666, polyclonal de lapin, https://www.abcam.com/ab30666
ab109401, monoclonal de lapin, https://www.abcam.com/ab109401
ab76128, polyclonal de lapin, https://www.abcam.com/ab76128
ab75603, monoclonal de lapin, https://www.abcam.com/ab75603

Si un anticorps n’a pas encore été testédans une application ou une espèce, il me sera possible de vous offrir une remise. Après soumission d’une Abreview avec vos résultats, unanticorpsvous sera offertlors d’une prochaine commande.

Etapes à suivre :

1. Nous confirmer que vous souhaiteriez tester abXXX dans une application ou une espèce qui n'est pas sur la fiche technique afin de recevoir le code de remise correspondant.Important,ce code doit être édité avant l’achat del'anticorps àtester

2. Acheter abXXX par téléphone, fax ou internet (https://www.abcam.com)

3. Le tester

4. Nous faire part de vos résultats, positifs ou négatifs, grâce à notre système Abreview. Pour plus d’informations https://www.abcam.com/abreviews

5. Après soumission de votre Abreview, appeler notre service clientèle afin de passer votre prochaine commande grâce au code de réduction. Ce code de réduction est utilisable 120 jours après son édition et utilisable lors de l’achat d’un autre anticorps primaire.
Même si abXXXne pas fonctionnepasdans la nouvelleapplication ou espèce, après soumission de votre Abreview, vous recevrez quand même un anticorps grauit.

N’hésitez pas à nous demander plus d’informations concernant cette offre promotionnelle.

Termes et Conditions : https://www.abcam.com/collaborationdiscount.

Read More

Answer

Thank you for taking the time to complete our questionnaire and contact us. I am sorry to hear you have had difficulty obtaining satisfactory results from this antibody.

The details you have kindly provided will provide us with vital information for our monitoring of product quality. I would like to reassure you that this antibody is tested and covered by our guarantee forrat and mouse and WB.

I appreciate the time you have spent in the laboratory and understand your concerns. It is regrettable the results have not been successful. Reviewing the details, I am sorry there arefew tips to provide on this occasion to help improve the results. I can suggest you have regrettably received a bad vial.

I can recommend you may like to consider trying the following options:

1. We recommend not to mix blocking agents in one experiment. I can suggest to try BSA only. Milk contains a lot of phosphorylated protein that can sometimes crossreact with antibodies that detect phosphorylated residues of target proteins.

2. I would recommend to incubate primary antibody overnight 4oC for each experiment.

3. Is the current vial of secondary antibody working well with other primary antibodies?

4. Has the protein transfer to the membrane and quality of the sample been assessed using a loading control?

Alternatively, or if these tips do not work, I am pleased to offer you a free of charge replacement or credit note in compensation.

Thank you for your cooperation. I look forward to hearing from you with details of how you would like to proceed.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up